These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28759004)

  • 1. A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF.
    Choi J; Xu M; Makowski MM; Zhang T; Law MH; Kovacs MA; Granzhan A; Kim WJ; Parikh H; Gartside M; Trent JM; Teulade-Fichou MP; Iles MM; Newton-Bishop JA; Bishop DT; MacGregor S; Hayward NK; Vermeulen M; Brown KM
    Nat Genet; 2017 Sep; 49(9):1326-1335. PubMed ID: 28759004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
    Bonet C; Luciani F; Ottavi JF; Leclerc J; Jouenne FM; Boncompagni M; Bille K; Hofman V; Bossis G; Marco de Donatis G; Strub T; Cheli Y; Ohanna M; Luciano F; Marchetti S; Rocchi S; Birling MC; Avril MF; Poulalhon N; Luc T; Hofman P; Lacour JP; Davidson I; Bressac-de Paillerets B; Ballotti R; Marine JC; Bertolotto C
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.
    Haq R; Yokoyama S; Hawryluk EB; Jönsson GB; Frederick DT; McHenry K; Porter D; Tran TN; Love KT; Langer R; Anderson DG; Garraway LA; Duncan LM; Morton DL; Hoon DS; Wargo JA; Song JS; Fisher DE
    Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4321-6. PubMed ID: 23447565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation.
    Kido K; Sumimoto H; Asada S; Okada SM; Yaguchi T; Kawamura N; Miyagishi M; Saida T; Kawakami Y
    Cancer Sci; 2009 Oct; 100(10):1863-9. PubMed ID: 19659611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXQ1 controls the induced differentiation of melanocytic cells.
    Bagati A; Bianchi-Smiraglia A; Moparthy S; Kolesnikova K; Fink EE; Kolesnikova M; Roll MV; Jowdy P; Wolff DW; Polechetti A; Yun DH; Lipchick BC; Paul LM; Wrazen B; Moparthy K; Mudambi S; Morozevich GE; Georgieva SG; Wang J; Shafirstein G; Liu S; Kandel ES; Berman AE; Box NF; Paragh G; Nikiforov MA
    Cell Death Differ; 2018 Jun; 25(6):1040-1049. PubMed ID: 29463842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation.
    Maurus K; Hufnagel A; Geiger F; Graf S; Berking C; Heinemann A; Paschen A; Kneitz S; Stigloher C; Geissinger E; Otto C; Bosserhoff A; Schartl M; Meierjohann S
    Oncogene; 2017 Sep; 36(36):5110-5121. PubMed ID: 28481878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory and functional connection of microphthalmia-associated transcription factor and anti-metastatic pigment epithelium derived factor in melanoma.
    Fernández-Barral A; Orgaz JL; Baquero P; Ali Z; Moreno A; Tiana M; Gómez V; Riveiro-Falkenbach E; Cañadas C; Zazo S; Bertolotto C; Davidson I; Rodríguez-Peralto JL; Palmero I; Rojo F; Jensen LD; del Peso L; Jiménez B
    Neoplasia; 2014 Jun; 16(6):529-42. PubMed ID: 25030625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.
    Yu H; McDaid R; Lee J; Possik P; Li L; Kumar SM; Elder DE; Van Belle P; Gimotty P; Guerra M; Hammond R; Nathanson KL; Dalla Palma M; Herlyn M; Xu X
    Am J Pathol; 2009 Jun; 174(6):2367-77. PubMed ID: 19389934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
    Kundu A; Quirit JG; Khouri MG; Firestone GL
    Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human skin neural crest progenitor cells are susceptible to BRAF(V600E)-induced transformation.
    Kumar SM; Dai J; Li S; Yang R; Yu H; Nathanson KL; Liu S; Zhou H; Guo J; Xu X
    Oncogene; 2014 Feb; 33(7):832-41. PubMed ID: 23334329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
    Wellbrock C; Rana S; Paterson H; Pickersgill H; Brummelkamp T; Marais R
    PLoS One; 2008 Jul; 3(7):e2734. PubMed ID: 18628967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BPTF transduces MITF-driven prosurvival signals in melanoma cells.
    Dar AA; Majid S; Bezrookove V; Phan B; Ursu S; Nosrati M; De Semir D; Sagebiel RW; Miller JR; Debs R; Cleaver JE; Kashani-Sabet M
    Proc Natl Acad Sci U S A; 2016 May; 113(22):6254-8. PubMed ID: 27185926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A genomic screen identifies TYRO3 as a MITF regulator in melanoma.
    Zhu S; Wurdak H; Wang Y; Galkin A; Tao H; Li J; Lyssiotis CA; Yan F; Tu BP; Miraglia L; Walker J; Sun F; Orth A; Schultz PG; Wu X
    Proc Natl Acad Sci U S A; 2009 Oct; 106(40):17025-30. PubMed ID: 19805117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
    Wellbrock C; Marais R
    J Cell Biol; 2005 Aug; 170(5):703-8. PubMed ID: 16129781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TFAP2 paralogs regulate melanocyte differentiation in parallel with MITF.
    Seberg HE; Van Otterloo E; Loftus SK; Liu H; Bonde G; Sompallae R; Gildea DE; Santana JF; Manak JR; Pavan WJ; Williams T; Cornell RA
    PLoS Genet; 2017 Mar; 13(3):e1006636. PubMed ID: 28249010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A conditional zebrafish MITF mutation reveals MITF levels are critical for melanoma promotion vs. regression in vivo.
    Lister JA; Capper A; Zeng Z; Mathers ME; Richardson J; Paranthaman K; Jackson IJ; Elizabeth Patton E
    J Invest Dermatol; 2014 Jan; 134(1):133-140. PubMed ID: 23831555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
    Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
    Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A role for ATF2 in regulating MITF and melanoma development.
    Shah M; Bhoumik A; Goel V; Dewing A; Breitwieser W; Kluger H; Krajewski S; Krajewska M; Dehart J; Lau E; Kallenberg DM; Jeong H; Eroshkin A; Bennett DC; Chin L; Bosenberg M; Jones N; Ronai ZA
    PLoS Genet; 2010 Dec; 6(12):e1001258. PubMed ID: 21203491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zebrafish MITF-Low Melanoma Subtype Models Reveal Transcriptional Subclusters and MITF-Independent Residual Disease.
    Travnickova J; Wojciechowska S; Khamseh A; Gautier P; Brown DV; Lefevre T; Brombin A; Ewing A; Capper A; Spitzer M; Dilshat R; Semple CA; Mathers ME; Lister JA; Steingrimsson E; Voet T; Ponting CP; Patton EE
    Cancer Res; 2019 Nov; 79(22):5769-5784. PubMed ID: 31582381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Massively parallel reporter assays of melanoma risk variants identify MX2 as a gene promoting melanoma.
    Choi J; Zhang T; Vu A; Ablain J; Makowski MM; Colli LM; Xu M; Hennessey RC; Yin J; Rothschild H; Gräwe C; Kovacs MA; Funderburk KM; Brossard M; Taylor J; Pasaniuc B; Chari R; Chanock SJ; Hoggart CJ; Demenais F; Barrett JH; Law MH; Iles MM; Yu K; Vermeulen M; Zon LI; Brown KM
    Nat Commun; 2020 Jun; 11(1):2718. PubMed ID: 32483191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.